[go: up one dir, main page]

MX2018003562A - Derivados de hidroxialquil tiadiazol. - Google Patents

Derivados de hidroxialquil tiadiazol.

Info

Publication number
MX2018003562A
MX2018003562A MX2018003562A MX2018003562A MX2018003562A MX 2018003562 A MX2018003562 A MX 2018003562A MX 2018003562 A MX2018003562 A MX 2018003562A MX 2018003562 A MX2018003562 A MX 2018003562A MX 2018003562 A MX2018003562 A MX 2018003562A
Authority
MX
Mexico
Prior art keywords
safety profile
excellent solubility
possess excellent
human
subunit
Prior art date
Application number
MX2018003562A
Other languages
English (en)
Other versions
MX376304B (es
Inventor
Kagoshima Yoshiko
Suzuki Tetsuya
Kumar Khera Manoj
Mathur Tarun
A Sattigeri Jitendra
Masuda Nobuhisa
Soneda Tsuyoshi
Konosu Toshiyuki
Yamaoka Makoto
Itooka Ryo
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MX2018003562A publication Critical patent/MX2018003562A/es
Publication of MX376304B publication Critical patent/MX376304B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a la necesidad de un nuevo antibiótico que tiene un mecanismo de acción novedoso, el cual presenta fuerte actividad antibacteriana no solamente contra la bacteria sensible, sino también contra la bacteria resistente del mismo, y al mismo tiempo posee excelente perfil de solubilidad y seguridad susceptible para usarse humano. Como un resultado de la investigación extensiva, los presentes inventores han encontrado que un compuesto representado por la fórmula general (I), (ver Fórmula) un estereoisómero, o una sal del mismo farmacéuticamente aceptable inhibe la subunidad GyrB de girasa de ADN y/o subunidad ParE de topoisomerasa IV, posee excelente perfil de seguridad y solubilidad para usarse en humano para el tratamiento de enfermedades infecciosas bacterianas.
MX2018003562A 2015-09-30 2016-09-28 Derivados de hidroxialquil tiadiazol. MX376304B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3119DE2015 2015-09-30
PCT/IB2016/055795 WO2017056012A1 (en) 2015-09-30 2016-09-28 Hydroxyalkyl thiadiazole derivatives

Publications (2)

Publication Number Publication Date
MX2018003562A true MX2018003562A (es) 2018-06-19
MX376304B MX376304B (es) 2025-03-07

Family

ID=57218949

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003562A MX376304B (es) 2015-09-30 2016-09-28 Derivados de hidroxialquil tiadiazol.

Country Status (18)

Country Link
US (1) US10399968B2 (es)
EP (1) EP3356361B1 (es)
JP (1) JP6824256B2 (es)
KR (1) KR20180054650A (es)
CN (1) CN108137574B (es)
AU (1) AU2016330271B2 (es)
BR (1) BR112018006276A2 (es)
CA (1) CA2999982C (es)
CO (1) CO2018003548A2 (es)
ES (1) ES2817749T3 (es)
IL (1) IL258411B (es)
MX (1) MX376304B (es)
MY (1) MY184406A (es)
PH (1) PH12018500697A1 (es)
RU (1) RU2737892C1 (es)
TW (1) TW201731844A (es)
WO (1) WO2017056012A1 (es)
ZA (1) ZA201801718B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018006276A2 (pt) * 2015-09-30 2018-10-16 Daiichi Sankyo Company, Limited composto, composição farmacêutica, e, inibidor de subunidade gyrb da dna girase e/ou subunidade pare de topoisomerase iv.
TW201840322A (zh) * 2017-03-14 2018-11-16 日商第一三共股份有限公司 羥烷基噻二唑衍生物之ｎ－膦醯基氧基甲基前驅藥
WO2020048949A1 (en) 2018-09-03 2020-03-12 Univerza V Ljubljani New class of dna gyrase and/or topoisomerase iv inhibitors with activity against gram-positive and gram-negative bacteria
EP4263503A1 (en) 2020-12-17 2023-10-25 Univerza V Ljubljani New n-phenylpyrrolamide inhibitors of dna gyrase and topoisomerase iv with antibacterial activity
CN115466246B (zh) * 2021-06-11 2024-02-06 中国医学科学院药物研究所 吡咯酰哌啶胺类化合物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
JP2008530192A (ja) 2005-02-18 2008-08-07 アストラゼネカ アクチボラグ Ｄｎａジャイレース及びトポイソメラーゼの阻害剤としてのピロール誘導体
CA2598423C (en) 2005-02-18 2014-05-27 Astrazeneca Ab Antibacterial piperidine derivatives
US20080161306A1 (en) 2005-02-18 2008-07-03 Brian Sherer Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors
WO2006092608A1 (en) 2005-03-04 2006-09-08 Astrazeneca Ab Tricyclic derivatives of azetidine and pyrrole with antibacterial activity
CN101171247A (zh) 2005-03-04 2008-04-30 阿斯利康(瑞典)有限公司 作为dna促旋酶和拓扑异构酶抑制剂的吡咯衍生物
WO2007071965A2 (en) 2005-12-23 2007-06-28 Astrazeneca Ab Antibacterial pyrrolopyridines, pyrrolopyrimidines, and pyrroloazepines
TW200819437A (en) * 2006-08-17 2008-05-01 Astrazeneca Ab Chemical compounds
WO2008020227A2 (en) 2006-08-17 2008-02-21 Astrazeneca Ab Antibacterial pyrrolecarboxamides
WO2008020229A2 (en) 2006-08-17 2008-02-21 Astrazeneca Ab Antibacterial pyrrolecarboxamides
TW200906412A (en) 2007-06-12 2009-02-16 Astrazeneca Ab Piperidine compounds and uses thereof
TWI498115B (zh) * 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
EP2326640A1 (en) 2008-07-30 2011-06-01 Ranbaxy Laboratories Limited Pyrrole carboxylic acid derivatives as antibacterial agents
US8071605B2 (en) 2008-12-12 2011-12-06 Astrazeneca Ab Piperidine compounds for use in the treatment of bacterial infections
TW201026694A (en) * 2008-12-12 2010-07-16 Astrazeneca Ab Compound 468
JP2011026305A (ja) 2009-06-24 2011-02-10 Daiichi Sankyo Co Ltd イミダゾールカルボニル化合物を含有する医薬組成物
EP2906216B1 (en) 2012-10-10 2020-06-24 Kumar, Ajay Inhibitors of dna gyrase for the treatment of bacterial infections
BR112018006276A2 (pt) * 2015-09-30 2018-10-16 Daiichi Sankyo Company, Limited composto, composição farmacêutica, e, inibidor de subunidade gyrb da dna girase e/ou subunidade pare de topoisomerase iv.

Also Published As

Publication number Publication date
ZA201801718B (en) 2019-01-30
US20180327399A1 (en) 2018-11-15
CN108137574B (zh) 2021-12-28
IL258411A (en) 2018-05-31
RU2737892C1 (ru) 2020-12-04
JP6824256B2 (ja) 2021-02-03
AU2016330271B2 (en) 2020-04-30
WO2017056012A1 (en) 2017-04-06
ES2817749T3 (es) 2021-04-08
JP2018529696A (ja) 2018-10-11
EP3356361A1 (en) 2018-08-08
US10399968B2 (en) 2019-09-03
CO2018003548A2 (es) 2018-07-19
HK1252275A1 (en) 2019-05-24
CA2999982C (en) 2020-07-28
IL258411B (en) 2021-08-31
MY184406A (en) 2021-04-01
TW201731844A (zh) 2017-09-16
AU2016330271A1 (en) 2018-04-12
MX376304B (es) 2025-03-07
BR112018006276A2 (pt) 2018-10-16
CA2999982A1 (en) 2017-04-06
KR20180054650A (ko) 2018-05-24
CN108137574A (zh) 2018-06-08
EP3356361B1 (en) 2020-07-08
PH12018500697A1 (en) 2018-10-01

Similar Documents

Publication Publication Date Title
PH12018500697A1 (en) Hydroxyalkyl thiadiazole derivatives
PH12016501972B1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MY199511A (en) Novel condensed pyrimidine compound or salt thereof
SG11201901061QA (en) Heterocyclic compound
NZ733174A (en) Quinazoline derivatives used to treat hiv
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
MY150939A (en) Oxazine derivatives and their use in the treatment of neurological disorders
PH12016501651B1 (en) Triazine compound and use thereof for medical purposes
MX2016009251A (es) Derivados de 7-oxo-1, 6-diazabiciclo [3.2.1] octano y su uso como agentes antibacterianos.
PH12016501349A1 (en) Hydroxy formamide derivatives and their use
PH12016501988A1 (en) Antibacterial compounds
MX2016016363A (es) Compuestos que comprenden un sistema de 1,1',2,5'-tetrahidroespiro [indol-3,2'-pirrol]-2,5'-diona como inhibidores de la interaccion de proteina-proteina p53-mdm2.
ZA201805358B (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
SA518390825B1 (ar) مضاد حيوي جديد فعال من أمينو جلايكوسيد للبكتيريا المضادة لعقاقير متعددة
EA201890412A1 (ru) АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ
HK1252245A1 (zh) 用於治疗癌症的核苷酸
MX379373B (es) Derivado de sulfonamida heterocíclico y medicina que contiene el mismo.
WO2015155680A3 (en) Pyrazole derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors
PH12016501645A1 (en) Aminopyrazolone derivative
TR201813294T4 (tr) N-aril-2-amino-4-aril-pirimidin makrosi̇kli̇k poli̇eter türevleri̇ ve bunlarin flt3 ve jak i̇nhi̇bi̇törleri̇ olarak kullanimlari.
NZ706393A (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
PH12016501215A1 (en) Azaindole derivative
WO2016072854A3 (en) Pantothenamide analogues
PL408526A1 (pl) Pochodne 4-benzoilo-1-(2,3-dichlorobenzoilo)tiosemikarbazydu, sposób ich wytwarzania oraz ich zastosowanie medyczne
GB2553685A (en) Novel éthynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis

Legal Events

Date Code Title Description
FG Grant or registration